116026-95-0

Basic information

• Product Name: TERT-BUTYL 4-FORMYLPYRIDIN-3-YLCARBAMATE
• Synonyms: 3-AMINOPYRIDINE-4-CARBOXALDEHYDE, 3-BOC PROTECTED;(4-FORMYL-PYRIDIN-3-YL)-CARBAMIC ACID TERT-BUTYL ESTER;N-Boc-3-amino-4-pyridine carboxzyaldehyde;3-Aminopyridine-4-carboxaldehyde, 3-BOC protected 95%;N-Boc-3-amino-4-formylpyridine;t-Butyl 4-formylpyridin-3-ylcarbamate;Carbamic acid, N-(4-formyl-3-pyridinyl)-, 1,1-dimethylethyl ester;TERT-BUTYL 4-FORMYLP
• CAS NO: 116026-95-0
• Molecular Formula: C₁₁H₁₄N₂O₃
• Molecular Weight: 222.24
• Product Categories: Aldehydes;Pyridines;Building Blocks;Pyridine
• Mol File: 116026-95-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 52-53 °C
• Boiling Point: 309.962 °C at 760 mmHg
• Flash Point: 141.26 °C
• Appearance: /
• Density: 1.212 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.58
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 12.42±0.70(Predicted)
• CAS DataBase Reference: TERT-BUTYL 4-FORMYLPYRIDIN-3-YLCARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-FORMYLPYRIDIN-3-YLCARBAMATE(116026-95-0)
• EPA Substance Registry System: TERT-BUTYL 4-FORMYLPYRIDIN-3-YLCARBAMATE(116026-95-0)

Safety Data

• Hazardous Substances Data: 116026-95-0(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-formylpyridin-3-ylcarbamate, also known as TFPyC, is a chemical compound with the molecular formula C13H18N2O3. It is a derivative of pyridine and is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. TFPyC is a white to off-white solid with a molecular weight of 250.29 g/mol and a melting point of 117-120°C. It is also known for its potential use as an antifungal agent due to its inhibitory effects on fungal pathogens. Additionally, TFPyC is used in various research and development applications, particularly in the field of organic synthesis and drug discovery processes.

InChI:InChI=1/C11H14N2O3/c1-11(2,3)16-10(15)13-9-6-12-5-4-8(9)7-14/h4-7H,1-3H3,(H,13,15)

Upstream product

• 2591-86-8 N-Formylpiperidine 
• 56700-70-0 3-(tert-butoxycarbonylamino)pyridine 
• 7647-01-0 hydrogenchloride 
• 7732-18-5 water 
• 180253-66-1 3-(tert-butyloxycarbonylamino)-4-methyl-pyridine 
• 3430-27-1 3-amino-4-methylpyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 594-19-4 tert.-butyl lithium 

Downstream Products

• 250674-49-8 1,7-naphthyridine-3-carboxylic acid 
• 486422-81-5 4-[(dimethylamino)methyl]pyridin-3-amine 
• 55234-64-5 2-oxo-1,2-dihydro-[1,7]naphthyridine-3-carboxylic acid ethyl ester 
• 316155-99-4 2-tert-butoxycarbonylamino-8-(4'-nitro-biphenyl-4-ylmethyl)-5,8-dihydro-6H-[1,7]naphthyridine-7-carboxylic acid ethyl ester 
• 316155-91-6 8-(4-benzyloxy-benzyl)-2-tert-butoxycarbonylamino-8H-[1,7]naphthyridine-7-carboxylic acid ethyl ester 
• 316156-07-7 2-amino-8-(4'-amino-biphenyl-4-ylmethyl)-5,8-dihydro-6H-[1,7]naphthyridine-7-carboxylic acid tert-butyl ester 
• 316155-95-0 2-tert-butoxycarbonylamino-8-(4-hydroxy-benzyl)-5,8-dihydro-6H-[1,7]naphthyridine-7-carboxylic acid ethyl ester 
• 316156-03-3 8-(4'-amino-biphenyl-4-ylmethyl)-5,6,7,8-tetrahydro-[1,7]naphthyridin-2-ylamine 
• 316155-87-0 2-carboxy-(1,6)-naphthyridine 
• 55279-29-3 3-amino-pyridine-4-carbaldehyde 
• 949922-44-5 ethyl 1,7-naphthyridine-3-carboxylate 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS

The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, Q, U, V, W, X, Z, m, n, and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

SUBSTITUTED AZACHINAZOLINES HAVING AN ANTIVIRAL ACTION

The invention relates to substituted azachinazolines and methods for the production thereof. The invention also relates to the use of said azachinazolines for producing medicaments for the treatment and/or prophylaxis of diseases, especially for using as antiviral agents, especially against cytomegaloviruses.

Inhibitors of Cyclic AMP Phosphodiesterase. 3. Synthesis and Biological Evaluation of Pyrido and Imidazolyl Analogues of 1,2,3,5-Tetrahydro-2-oxoimidazoquinazoline

Hybridization of structural elements of 1,2,3,5-tetrahydro-2-oxoimidazoquinazoline ring system common to the cyclic AMP (cAMP) phosphodiesterase (PDE) inhibitors lixazinone (RS-82856,1) and anagrelide (3) with complementary features of other PDE inhibitor cardiotonic agents prompted the design and synthesis of the title compounds 7a-d, 11, 12, and 13a,b.The necessary features of these compounds were determined within the framework of the proposed active-site models for the high affinity form of cAMP PDE inhibited by cGMP (type IV).Evaluation of these targets, both in vitro as inhibitors of platelet or cardiac type IV PDE or in vivo as inotropic agents in the pentobarbital-anesthetized dog model of congestive heart failure, showed that these structure possessed negligibly enhanced activities over the parent heterocyclic system, and remained significantly inferior to 1 in all respects.This difference is ascribed to the absence of the N-cyclohexyl-N-methylbutyramidyl-4-oxy side chain of 1.The proposal that the acidic lactam-type functionality, common to the type IV PDE inhibitor inotropic agents such as 4-6 and 8-10, mimics the polarizable cyclic phosphate moiety of cAMP suggested that the side chain of 1 may function as an effective surrogate for selected characteristics of the adenine portion of cAMP.However, the results of this study show that incorporation of adenine-like hydrogen-bonding functionalities common to other type IV PDE inhibitors into the 1,2,3,5-tetrahydro-2-oxoimidazoquinazoline system did not enhance activity to the levels observed for 1 analogues.These observations, coupled with the kinetic pattern of inhibition of type IV PDE observed for 1 and analogues, suggest that access to a secondary, lipophilic-tolerant binding site, possibly coincident with the adenine binding domain, and adjacent to the catalytic ribose-phosphate binding site of platelet and cardiac type IV PDE, is responsible for the increased potency of these compounds.